The regulatory decision gives the devices the green light to be used in artificial pancreas systems, and positions Abbott as a competitor to Dexcom in the space.
Abbott CGMs cleared to integrate with automated insulin delivery systems Read More »
While the extra time to comply is aimed at preventing medical device shortages, the rules have still left some device makers and certifying bodies unclear about how to proceed, says one attorney.
Medtech industry relieved as Europe’s MDR extension nears final approval Read More »
Una investigación reciente ha analizado los servicios de interacciones falsas en las redes sociales. Además de catalogar el ecosistema fraudulento de “likes”, reproducciones, seguidores o visitas online, el estudio señala los modelos económicos que lo sustenta …
Los servicios de interacciones falsas en las redes sociales, al descubierto Read More »
Voyager Therapeutics unlocked a potential $600 million plus $25 million upfront as Novartis exercised its option to leverage the company’s capsids against two undisclosed neurologic disease targets.
Voyager Rolls on as Novartis Selects Two of Three CNS Targets Read More »
The transcatheter repair clip beat the established medical therapy on the primary composite endpoint, setting up a battle with a rival company for a $5 billion market.
Follow along as BioSpace keeps you up-to-date on which companies are tightening their belts and cutting staff throughout 2023.
BioSpace Layoff Tracker 2023: atai, MorphoSys, G1 and More Cut Staff Read More »
The FDA set a decision date of July 6, 2023 for Eisai and Biogen’s recently approved Alzheimer’s drug, Leqembi, Eisai announced Monday.
FDA Sets July Decision Date for Full Approval of Leqembi Read More »
With the results from the CLEAR outcomes study, Esperion is poised for a major inflection in sales and is targeting blockbuster status, said CEO Sheldon Koenig on an investor call Monday.
Full Results from Esperion’s Cholesterol Drug Fail to Impress Investors Read More »
Here are some tips to help you nail virtual interviews and networking events so you can be prepared for BioSpace’s Virtual Talent Connect on March 9.
How to Nail Virtual Interviews & Networking Events Read More »
Incyte Corporation’s Phase III LIMBER-304 clinical trial has come to an end following a third-party investigation that forecasted poor results.
Incyte Abandons Phase III Trial for Myelofibrosis Treatment Read More »
